News
-
-
-
-
PRESS RELEASE
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Eurofins bought back 70,000 shares from June 16th to June 20th, 2025, with daily weighted average purchase price of 60.0627. Transaction details available on Eurofins Scientific SE website -
-
-
REGULATED PRESS RELEASE
Disclosure of transactions in own shares from June 16 to June 20, 2025
-
PRESS RELEASE
Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
Biotest AG announces positive phase III trial results for fibrinogen concentrate BT524 in reducing bleeding, with potential regulatory approval in Europe and U.S. pending. Study data to be presented at ISTH 2025 Congress -
-
PRESS RELEASE
Xebra Announces Corporate Update and Correction Notice of Press Release Announcing Grant of Management Cease Trade Order
Xebra Brands announces correction to press release, management changes, warrant extension. Company focuses on cannabis products, global brands, and intellectual property